Pharmacological Effects and Toxicity Studies
Research Guide

Epilepsy is defined as a disorder of the brain characterized by an enduring predisposition to generate epileptic seizures, practically applied as having two unprovoked seizures more than 24 hours apart. This definition from Fisher et al. (2014) in "ILAE Official Report: A practical clinical definition of epilepsy" (5618 citations) guides antiepileptic drug therapy and toxicity evaluations. It supports standardized assessment of maternal epilepsy impacts on fetal development.

Drug resistant epilepsy is identified in patients who have many seizures before therapy or show inadequate response to initial antiepileptic drugs. Kwan and Brodie (2000) in "Early Identification of Refractory Epilepsy" (5034 citations) established this criterion. The consensus definition from Kwan et al. (2009) in "Definition of drug resistant epilepsy: Consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies" (4532 citations) provides a hierarchical framework with general and practical levels for clinical use.

Studies focus on teratogenicity, neurodevelopmental disorders, cognitive function, bone health, oxidative stress, and malformations from prenatal antiepileptic drug exposure. Maternal epilepsy impacts fetal development, as covered in the 139,956 works in this cluster. Scheffer et al. (2017) in "ILAE classification of the epilepsies: Position paper of the ILAE Commission for Classification and Terminology" (4654 citations) updates classifications to reflect mechanisms relevant to toxicity.

ILAE definitions standardize terms like epileptic seizure and epilepsy for pharmacological and toxicity studies. Fisher et al. (2005) in "Epileptic Seizures and Epilepsy: Definitions Proposed by the International League Against Epilepsy (ILAE) and the International Bureau for Epilepsy (IBE)" (3532 citations) describe an epileptic seizure as a transient occurrence of signs due to abnormal excessive or synchronous neuronal activity. These aid in evaluating drug effects on neurodevelopment.

Pharmacological effects include clinical benefits from drugs like gemcitabine, though primarily studied in pancreas cancer by Burris et al. (1997) in "Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial." (5839 citations). In epilepsy, antiepileptic drugs target seizure control but carry prenatal toxicity risks. Refractory cases per Kwan and Brodie (2000) necessitate advanced interventions.